Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F22%3A10441721" target="_blank" >RIV/00064203:_____/22:10441721 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QcdJsj8oTc" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=QcdJsj8oTc</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3324/haematol.2021.279507" target="_blank" >10.3324/haematol.2021.279507</a>
Alternative languages
Result language
angličtina
Original language name
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
Original language description
In neonates with myeloid hyperproliferation, apart from benign causes, Down syndrome (DS) related transient abnormal myelopoiesis (TAM), acute myeloid leukemia (AML) and juvenile myelomonocytic leukemia (JMML) are considered. Besides TAM, rarely, non-DS related transient myeloproliferative diseases occur, making clinical decisions challenging.4 TAM, according to World Health Organization (WHO) classification, only applies to children with (mosaic) Down syndrome.5 In the past, different terminology has been used in non-DS patients, such as transient myeloproliferative disease (TMD) and transient leukemia. Since distinction from TAM is important, and it is challenging to determine whether this disease will be transient, the consensus group introduced the novel term 'infantile myeloproliferative disease' (IMD), in order to distinguish it from TAM. Both TAM and IMD can usually be managed with a 'watch and wait' strategy, while most fullblown AML or JMML cases require intensive treatment. We collected rare IMD cases from study groups collaborating in the International Berlin-Frankfurt-Münster AML Study Group (I-BFM AML SG). In addition, we reviewed the literature for neonatal cases of malignant myeloid hyperproliferation without DS. Based on these data, we developed, together with I-BFM AML SG and the European Working Group of Myelodysplastic syndromes in Childhood (EWOG-MDS) members, by consensus, clinical recommendations for the diagnostic approach and current adequate classification of malignant myeloid hyperproliferation in infancy. This is meant guiding clinicians in choosing the right strategy, i.e., whether to 'watch and wait' or start highly intensive treatment in individual cases.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Haematologica
ISSN
0390-6078
e-ISSN
—
Volume of the periodical
107
Issue of the periodical within the volume
3
Country of publishing house
IT - ITALY
Number of pages
4006
Pages from-to
759-4764
UT code for WoS article
000811240400056
EID of the result in the Scopus database
2-s2.0-85125554397